This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
million, his first big raise since 2015, thanks to incentive pay that jumped by about $1.2 million in 2020, more than double the number in 2015, according to health data company IQVIA. Food and Drug Administration (FDA) is meant to help patients and warn of potential drug sideeffects but a Vice report indicates something more.
a China-based pharma company has announced it has received clearance for its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to initiate clinical studies of T21, a 3D-printed medicine that can target specific segments in the colon to more safely deliver oral ulcerative colitis (UC) drugs.
This is especially beneficial as a way of decreasing potential sideeffects. In the years 2015 and 2020, clinical-stage cancer programmes increased by a considerable 77 percent (1,642 to 2,911), resulting in a quarter of drugs currently in development worldwide being highly potent.
The FDA has issued a complete response letter (CRL) to Spectrum Pharma for poziotinib, its pan HER2 inhibitor for a form of lung cancer, according to South Korea’s Hanmi Pharma, which originally developed the drug. Spectrum licensed worldwide rights to poziotinib – excluding Korea and China – from Hanmi in back in 2015.
Patients with end-stage renal disease (ESRD) who are on dialysis often need to be treated with anticoagulants to prevent blood clots, but as a result, can experience bleeding sideeffects. Now, Ionis and Bayer think they have a new drug that could sidestep that risk.
There is an urgent need for more effective chemotherapy treatments with less severe toxicity and sideeffects. Irinotecan – also known by the brand name Campto/Camptosar ® (Pfizer Ltd.) – has proven to be an effective chemotherapy agent against several types of gastrointestinal cancer. 2015; 35(3):1437-45.
The FDA maintains an Adverse Event Reporting System dashboard that allows the public to view data built from adverse event reports filed by healthcare professionals, the pharma industry, and consumers. Apetamin, in the form of tablets and syrup, is still available on several online sites, including stores on the popular marketplace Etsy.
Advanz Pharma, which markets the drug in Europe, needed confirmatory data from further clinical studies to maintain its conditional marketing authorisation granted in 2016. Due to the issues with Ocaliva, there is space for competitors with fewer sideeffects and Calliditas hopes that setanaxib will fit the bill. Chueng, et al.
Between 2015 and 2021, over a quarter of the drugs approved by the US Food and Drug Administration (FDA) were associated with specific biomarkers. Precision Medicine Redefined Keeping pace with the times, many health and pharma companies have even embraced novel technologies and partnered with technology giants to drive innovation.
In recent years, social media has evolved into an essential part of pharma operations, for better or worse. Below, I’m exploring a few ways that pharma teams are using social media and other online collaboration platforms to connect, educate, and influence. Healthcare Provider (HCP) marketing. Congress Coverage.
After more than a decade in development, Freya Pharma Solutions plans to advance an oral tablet dubbed Lybrido into Phase III trials to treat female sexual interest/arousal disorder (FSIAD). Moreover, despite the buzz generated when Addyi was launched in 2015, only one other drug has since been marketed.
A couple of years ago, I first wrote about how social media’s role in the Pharma and healthcare sectors has been growing exponentially. In recent years, social media has evolved into an essential part of Pharma operations, for better or worse. . Pharma companies have to be careful when considering their involvement.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content